SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO § 240.13d-2

(Amendment No. 1)*

 

 

Angion Biomedica Corp.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

03476J107

(CUSIP Number)

December 31, 2022

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

  ☐

Rule 13d-1(b)

 

  ☐

Rule 13d-1(c)

 

  ☒

Rule 13d-1(d)

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

CUSIP No. 03476J107    13G    Page 2 of 6 Pages

 

 

  1.    

  NAME OF REPORTING PERSONS

 

  Itzhak D. Goldberg
  2.  

  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

  (a)  ☐     (b)  ☐

 
  3.  

  SEC USE ONLY

 
  4.  

  CITIZENSHIP OR PLACE OF ORGANIZATION

 

  USA

NUMBER OF

SHARES

 BENEFICIALLY 

OWNED BY

EACH

REPORTING

PERSON

WITH

    5.     

  SOLE VOTING POWER

 

  1,809,294*
   6.   

  SHARED VOTING POWER

 

  0
   7.   

  SOLE DISPOSITIVE VOTING POWER

 

  1,809,294*
   8.   

  SHARED DISPOSITIVE VOTING POWER

 

  0
  9.    

  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

  1,809,294
10.  

  CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

 

  ☐
11.  

  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

 

  6.0%**
12.  

  TYPE OF REPORTING PERSON

 

  IN

 

*

Consists of (1) 1,687,986 shares of Common Stock held directly by the Reporting Person, and (2) 121,308 shares of Common Stock underlying options exercisable within sixty days. Numbers of shares are reported as of February 8, 2023.
**

Based on 30,113,703 shares of Common Stock issued and outstanding as of November 8, 2022, as reported by the Issuer in its most recent Form 10-K filed November 14, 2022.

CUSIP No. 03476J107    13G    Page 3 of 6 Pages

 

Item 1(a).

Name of Issuer:

Angion Biomedica Corp.

 

Item 1(b).

Address of Issuer’s Principal Executive Offices:

51 Charles Lindbergh Boulevard, Uniondale, NY 11553

 

Item 2(a).

Name of Person Filing:

This Schedule 13G is being filed by Itzhak D. Goldberg (the “Reporting Person”).

 

Item 2(b).

Address of Principal Business Office, or if None, Residence:

41 Brayton Street

Englewood, NJ 07631

 

Item 2(c).

Citizenship:

The Reporting Person is a citizen of the United States.

 

Item 2(d).

Title of Class of Securities:

Common Stock, par value $0.01 per share (“Common Stock”)

 

Item 2(e).

CUSIP Number:

03476J107

 

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

 

(a)    ☐    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
(b)    ☐    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)    ☐    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)    ☐    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)    ☐    An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)    ☐    An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)    ☐    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)    ☐    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)    ☐    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
(j)    ☐    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
(k)    ☐    Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

CUSIP No. 03476J107    13G    Page 4 of 6 Pages

 

Item 4.

Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

Reference is made to Items 5-9 and 11 and the footnotes thereto on page 2 of this Schedule 13G, which are incorporated by reference herein.

 

Item 5.

Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following  ☐.

 

Item 6.

Ownership of More Than Five Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

Not Applicable.

 

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

If a parent holding company or control person has filed this schedule, pursuant to § 240.13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

Not Applicable.

 

Item 8.

Identification and Classification of Members of the Group.

If a group has filed this schedule pursuant to § 240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group.

Not Applicable.

 

Item 9.

Notice of Dissolution of Group.

Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. (See Item 5.)

Not Applicable.

CUSIP No. 03476J107    13G    Page 5 of 6 Pages

 

Item 10.    Certifications.

Not Applicable.

CUSIP No. 03476J107    13G    Page 6 of 6 Pages

 

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 14, 2023

 

By:  

/s/ Itzhak D. Goldberg
  Itzhak D. Goldberg
Angion Biomedica (NASDAQ:ANGN)
Historical Stock Chart
From Aug 2023 to Sep 2023 Click Here for more Angion Biomedica Charts.
Angion Biomedica (NASDAQ:ANGN)
Historical Stock Chart
From Sep 2022 to Sep 2023 Click Here for more Angion Biomedica Charts.